304 related articles for article (PubMed ID: 34262941)
41. Comprehensive Analysis of the Correlation Between Pyroptosis-Related LncRNAs and Tumor Microenvironment, Prognosis, and Immune Infiltration in Hepatocellular Carcinoma.
Qu G; Wang D; Xu W; Guo W
Front Genet; 2022; 13():867627. PubMed ID: 35559014
[No Abstract] [Full Text] [Related]
42. Exploration and validation of a novel prognostic signature based on comprehensive bioinformatics analysis in hepatocellular carcinoma.
Wang X; Qiao J; Wang R
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33111935
[TBL] [Abstract][Full Text] [Related]
43. Novel Hypoxia-Related Gene Signature for Risk Stratification and Prognosis in Hepatocellular Carcinoma.
Li Q; Jin L; Jin M
Front Genet; 2021; 12():613890. PubMed ID: 34194464
[TBL] [Abstract][Full Text] [Related]
44. Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma.
Xia X; Tang P; Liu H; Li Y
J Clin Transl Hepatol; 2021 Dec; 9(6):798-808. PubMed ID: 34966643
[TBL] [Abstract][Full Text] [Related]
45. MAPK-RAP1A Signaling Enriched in Hepatocellular Carcinoma Is Associated With Favorable Tumor-Infiltrating Immune Cells and Clinical Prognosis.
Li H; Han G; Li X; Li B; Wu B; Jin H; Wu L; Wang W
Front Oncol; 2021; 11():649980. PubMed ID: 34178637
[TBL] [Abstract][Full Text] [Related]
46. N6-Methyladenine-Related Signature for Immune Microenvironment and Response to Immunotherapy in Hepatocellular Carcinoma.
Ren SH; Qin YF; Qin H; Wang HD; Li GM; Zhu YL; Sun CL; Shao B; Zhang JY; Hao JP; Wang H
Int J Gen Med; 2022; 15():3525-3540. PubMed ID: 35386863
[TBL] [Abstract][Full Text] [Related]
47. Identifying Dendritic Cell-Related Genes Through a Co-Expression Network to Construct a 12-Gene Risk-Scoring Model for Predicting Hepatocellular Carcinoma Prognosis.
Huang C; Jiang X; Huang Y; Zhao L; Li P; Liu F
Front Mol Biosci; 2021; 8():636991. PubMed ID: 34109210
[TBL] [Abstract][Full Text] [Related]
48. Molecular subtypes based on immune-related genes predict the prognosis for hepatocellular carcinoma patients.
Hu B; Yang XB; Sang XT
Int Immunopharmacol; 2021 Jan; 90():107164. PubMed ID: 33172741
[TBL] [Abstract][Full Text] [Related]
49. Construction and validation of a prognostic signature using CNV-driven genes for hepatocellular carcinoma.
Bian J; Long J; Yang X; Yang X; Xu Y; Lu X; Guan M; Sang X; Zhao H
Ann Transl Med; 2021 May; 9(9):765. PubMed ID: 34268378
[TBL] [Abstract][Full Text] [Related]
50. Development and Validation of a Pyroptosis-Related Signature for Predicting Prognosis in Hepatocellular Carcinoma.
Ding J; He X; Luo W; Zhou W; Chen R; Cao G; Chen B; Xiong M
Front Genet; 2022; 13():801419. PubMed ID: 35140750
[TBL] [Abstract][Full Text] [Related]
51. Machine Learning for Building Immune Genetic Model in Hepatocellular Carcinoma Patients.
Liu J; Chen Z; Li W
J Oncol; 2021; 2021():6676537. PubMed ID: 33790969
[TBL] [Abstract][Full Text] [Related]
52. Development and Validation of a Novel 8 Immune Gene Prognostic Signature Based on the Immune Expression Profile for Hepatocellular Carcinoma.
Xu D; Wang Y; Zhou K; Wu J; Zhang Z; Zhang J; Yu Z; Liu L; Liu X; Li B; Zheng J
Onco Targets Ther; 2020; 13():8125-8140. PubMed ID: 32884295
[TBL] [Abstract][Full Text] [Related]
53. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
Mo Z; Liu D; Rong D; Zhang S
Front Immunol; 2021; 12():611058. PubMed ID: 33679749
[No Abstract] [Full Text] [Related]
54. Characterization of chromatin regulators in hepatocellular carcinoma to guide clinical therapy.
Jia X; Zhang G
Front Genet; 2022; 13():961018. PubMed ID: 36092923
[No Abstract] [Full Text] [Related]
55. Characterization of cellular senescence patterns predicts the prognosis and therapeutic response of hepatocellular carcinoma.
Tang Y; Guo C; Chen C; Zhang Y
Front Mol Biosci; 2022; 9():1100285. PubMed ID: 36589233
[No Abstract] [Full Text] [Related]
56. Construction and validation of a prognostic marker and risk model for HCC ultrasound therapy combined with WGCNA identification.
Bi Y; Jing Y; Guo L
Front Genet; 2022; 13():1017551. PubMed ID: 36263426
[No Abstract] [Full Text] [Related]
57. Establishment and Validation of a Peroxisome-related Gene Signature for Prognostic Prediction and Immune Distinction in Hepatocellular Carcinoma.
Miao D; Xu Q; Zeng Y; Zhao R; Song X; Chen Z; Zeng L; Zhao L; Lin Z; Yu F
J Cancer; 2022; 13(5):1418-1435. PubMed ID: 35371321
[No Abstract] [Full Text] [Related]
58. Risk Predictive Model Based on Three DDR-Related Genes for Predicting Prognosis, Therapeutic Sensitivity, and Tumor Microenvironment in Hepatocellular Carcinoma.
Hu R; Liang X; Li Q; Liu Y
J Oncol; 2022; 2022():4869732. PubMed ID: 36213834
[TBL] [Abstract][Full Text] [Related]
59. Significance of tumor-infiltrating immunocytes for predicting prognosis of hepatitis B virus-related hepatocellular carcinoma.
Chen QF; Li W; Wu PH; Shen LJ; Huang ZL
World J Gastroenterol; 2019 Sep; 25(35):5266-5282. PubMed ID: 31558872
[TBL] [Abstract][Full Text] [Related]
60. Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature.
Zhao K; Xu L; Li F; Ao J; Jiang G; Shi R; Chen F; Luo Q
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32789471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
